Clinical Scorecard: Prula-cel Phase I Data Reported in SLE
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Prula-cel Shows Early Promise in Lupus
Key Mechanisms
Prulacabtagene leucel (prula-cel; formerly ADI-001) is an investigational allogeneic gamma delta CAR T therapy designed to target B cells through an anti-CD20 CAR. Adicet reported that all 22 efficacy-evaluable patients achieved undetectable CD19-positive B cells, followed by naïve-dominant B-cell reconstitution.
Target Population
Patients or participants described in the source article.
Care Setting
Prula-cel was studied in a Phase I clinical trial. Adicet reported that the FDA supported outpatient administration; routine-care use is not established in the source.
Key Highlights
Among 22 efficacy-evaluable patients, 54% of those evaluable at 12 months achieved DORIS remission.
Among evaluable lupus nephritis patients, 50% achieved a complete renal response at 12 months.
All efficacy-evaluable patients discontinued immunosuppressants; all but one reduced background corticosteroids to 5 mg or less of prednisone equivalent daily.
Among 24 safety-evaluable patients, Grade 1 or 2 CRS occurred in 25%; no CRS above Grade 2 or cases of ICANS, IEC-HS, graft-versus-host disease, or dose-limiting toxicity were reported.
Infections occurred in 54% of safety-evaluable patients, including Grade 3 or higher infections in 8.3%.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Prula-cel is investigational. Adicet describes it as an off-the-shelf, single-dose therapy. In the reported study, all efficacy-evaluable patients discontinued immunosuppressants, and all but one reduced corticosteroids to 5 mg or less of prednisone equivalent daily. Adicet reported that responses observed at 12 months were generally maintained through 12–21 months.
